NCT06228391View on ClinicalTrials.gov

Ketamine Treatment for PTSD and MDD in TBI

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
PTSD, Post Traumatic Stress DisorderMajor Depressive DisorderTraumatic Brain Injury
Interventions
DRUG

IV ketamine

Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.

DRUG

Midazolam

Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.

Trial Locations (1)

55417

Minneapolis VA Medical Center, Minneapolis

All Listed Sponsors
lead

Minneapolis Veterans Affairs Medical Center

FED

NCT06228391 - Ketamine Treatment for PTSD and MDD in TBI | Biotech Hunter | Biotech Hunter